ArticleNeural plasticity2015
Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation.
Article in Neural plasticity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Nabiximols in Multiple Sclerosis: Beyond Spasticity-An Exploratory Systematic Review and Meta-Analysis of Symptomatic Outcomes.Medical sciences (Basel, Switzerland) · 2026Pooled it
- The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: Rationale, study design, and methodology.Medicine · 2017Trial
- Cannabinoids in rehabilitation medicine: From controversy to clinical potential.Turkish journal of physical medicine and rehabilitation · 2026Article
- Radical Revelations: The Interplay of Nitrosative Stress, the Endocannabinoid System, and Treatment of Age-Related Disorders.International journal of molecular sciences · 2026Review
- Cannabidiol in Neurology: Current Insights and Translational Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Exploring the interconnected properties of cannabidiol suspensions and orodispersible films.Scientific reports · 2025Article
- The corticospinal tract in multiple sclerosis: correlation between cortical excitability and magnetic resonance imaging measures.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Trends in prescription and cost of Sativex, a cannabinoid-based medicine, in treating patients with multiple sclerosis in England.Journal of pharmaceutical policy and practice · 2024Article
- The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of SativexMini reviews in medicinal chemistry · 2024Review
- The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.International journal of molecular sciences · 2021Review
- Review
- The Influence of Recreational Substance Use in TMS Research.Brain sciences · 2020Review
- The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Review
- Cannabinoids and the expanded endocannabinoid system in neurological disorders.Nature reviews. Neurology · 2020Review
- Cannabinoid-induced alteration of motor-evoked potentials (MEPs) prior to intradural spinal tumor removal: a nasty surprise.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2018Article
- [What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity].Der Nervenarzt · 2017Review
- Efficacy and Tolerability of Phytomedicines in Multiple Sclerosis Patients: A Review.CNS drugs · 2017Review
- Review
- Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.Therapeutic advances in neurological disorders · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sativex is an emergent treatment option for spasticity in patients affected by multiple sclerosis (MS). This oromucosal spray, acting as a partial agonist at cannabinoid receptors, may modulate the balance between excitatory and inhibitory neurotransmitters, leading to muscle relaxation that is in turn responsible for spasticity improvement. Nevertheless, since the clinical assessment may not be sensitive enough to detect spasticity changes, other more objective tools should be tested to better define the real drug effect. The aim of our study was to investigate the role of Sativex in improving spasticity and related symptomatology in MS patients by means of an extensive neurophysiological assessment of sensory-motor circuits. To this end, 30 MS patients underwent a complete clinical and neurophysiological examination, including the following electrophysiological parameters: motor threshold, motor evoked potentials amplitude, intracortical excitability, sensory-motor integration, and Hmax/Mmax ratio. The same assessment was applied before and after one month of continuous treatment. Our data showed an increase of intracortical inhibition, a significant reduction of spinal excitability, and an improvement in spasticity and associated symptoms. Thus, we can speculate that Sativex could be effective in reducing spasticity by means of a double effect on intracortical and spinal excitability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.